**Author Information** An event is serious (based on the ICH definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* other medically important event

In a tele-dermatology study of 167 patients conducted, 5 patients (4 women and 1 man) aged 30−54 years were described, who developed COVID-19 following treatment with rituximab, prednisolone, methylprednisolone or azathioprine for pemphigus vulgaris \[*routes and duration of treatments to reaction onset not stated; not all dosages stated*\].

Patient 1: A 42-year-old woman, who was diagnosed with pemphigus vulgaris, received immunosuppression therapy with rituximab that started on 5 February 2018. Additionally, she received prednisolone every day. Subsequently, she developed fever, vomiting, nausea and myalgia. CT scan confirmed the diagnosis of COVID-19. Therefore, she was kept in home quarantine and received off label therapy with hydroxychloroquine 200 mg/day for two weeks. Concurrently, she also received supportive therapy with amoxicillin/clavulanic-acid \[co-amoxiclav\]. Eventually, her COVID-19 resolved, and she had no recurrence of COVID-19 thereafter.

Patient 2: A 54-year-old woman, who was diagnosed with pemphigus vulgaris, received immunosuppression therapy with rituximab on 12 December 2016 . Additionally, she received prednisolone every day. Subsequently, she developed fever, vomiting and myalgia. A CT scan confirmed the diagnosis of COVID-19. Therefore, she was kept home quarantine and received off label treatment with hydroxychloroquine 200 mg/day for two weeks. Concurrently, she also received supportive therapy with vitamin B complex, bromhexine and ketorolac. Eventually, her COVID-19 resolved and she had no recurrence of COVID-19 thereafter.

Patient 3: A 48-year-old smoker man, who was diagnosed with pemphigus vulgaris, received immunosuppression therapy with rituximab that started on 27 December 2014. Additionally, he received prednisolone every day, methylprednisolone and azathioprine. Subsequently, he developed fever, dry cough, nausea, vomiting and myalgia. A CT scan confirmed the diagnosis of COVID-19. Therefore, he was kept in home quarantine and received off label therapy with hydroxychloroquine 200 mg/day for two weeks. Eventually, his COVID-19 resolved, and he had no recurrence of COVID-19 thereafter.

Patient 4: A 35-year-old woman, who was diagnosed with pemphigus vulgaris, received immunosuppression therapy with rituximab that started on 09 August 2015. Additionally, she received prednisolone every day. A CT scan confirmed the diagnosis of COVID-19 although she was asymptomatic. Therefore, she was kept in home quarantine and received off label therapy with hydroxychloroquine 200 mg/day for two weeks. Eventually, her COVID-19 resolved, and she had no recurrence of COVID-19 thereafter.

Patient 5: A 30-year-old woman, who was diagnosed with pemphigus vulgaris, received immunosuppression therapy with rituximab that started on 04 December 2015. Additionally, she received prednisolone every day, methylprednisolone and azathioprine. Subsequently, she developed dyspnoea, fever, dry cough, nausea, and myalgia. A CT scan confirmed the diagnosis of COVID-19. Therefore, she was kept in home quarantine and received off label therapy with hydroxychloroquine 200 mg/day for two weeks. Eventually, her COVID-19 resolved, and she had no recurrence of COVID-19 thereafter.
